EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Use of Biologics for Thyroid Eye Disease

Shoaib Ugradar, Emanuil Parunakian, Raymond S Douglas

BioDrugs · 2025-07 · 39 (4) · 607-619

DOI: 10.1007/s40259-025-00726-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioDrugs, online erschienen am 06.06.2025. Verfasst von Shoaib Ugradar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Private Practice, 9675 Brighton Way Suite 410, Beverly Hills, CA, 90210, USA. Shoaib.ugradar@gmail.com. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Biological Products. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 105 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid eye disease (TED) is the most common extrathyroidal manifestation of Graves' disease. It is an autoimmune disorder that may present with signs of inflammation and extracellular matrix modification, leading to the characteristic features of swelling within the orbit, proptosis, diplopia, and vision loss. Recently, a growing body of work has focused on novel therapies for the treatment of TED. We review novel therapeutic agents aimed at treating TED. A review of the literature was performed through search of PubMed, Scopus, and Web of Science databases for terms related to the treatment of TED. There are multiple therapeutic agents available for the treatment of TED, focusing on the different molecular pathways that are dysregulated in the pathogenesis of the condition. Therapeutic targets include: B cells (rituximab), cytokines (interleukin [IL]-6] and IL-11), insulin-like growth factor 1 receptor, and antibodies (neonatal fragment crystallizable receptor). Currently, clinical evidence supports the use of anti-insulin-like growth factor 1 receptor therapy. However, research involving anti-IL-11, anti-IL-6, and the neonatal fragment crystallizable receptor is promising.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves OphthalmopathyBiological ProductsHumansReceptor, IGF Type 1Animals

Substanzen

Biological ProductsReceptor, IGF Type 1

Autor:innen und Institutionen

  • Private Practice, 9675 Brighton Way Suite 410, Beverly Hills, CA, 90210, USA. Shoaib.ugradar@gmail.com.
  • David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
  • Private Practice, 9675 Brighton Way Suite 410, Beverly Hills, CA, 90210, USA.

Zitieren

APA

Ugradar, S., Parunakian, E., & Douglas, R. S. (2025). The Use of Biologics for Thyroid Eye Disease. BioDrugs, 39(4), 607-619. https://doi.org/10.1007/s40259-025-00726-0

Vancouver

Ugradar S, Parunakian E, Douglas RS. The Use of Biologics for Thyroid Eye Disease. BioDrugs. 2025;39(4):607-619. doi:10.1007/s40259-025-00726-0

BibTeX
@article{Ugradar2025,
  author = {Ugradar, Shoaib and Parunakian, Emanuil and Douglas, Raymond S},
  title = {The Use of Biologics for Thyroid Eye Disease},
  journal = {BioDrugs},
  year = {2025},
  volume = {39},
  number = {4},
  pages = {607--619},
  doi = {10.1007/s40259-025-00726-0}
}
Kostenlos starten →